Articles tagged with T Lymphocytes
Researchers from Penn Medicine and Harvard University have developed a novel CAR T cell therapy that targets glioblastoma, a deadly brain cancer. The phase I trial has shown promising results, with patients experiencing significant expansion of engineered T cells in their blood and infiltration of tumors.
Scientists have created T cells that can recognize and destroy cancer cells in pancreatic tumors. The engineered cells were able to attack tumor cells for up to 10 days without harming healthy tissues.
Researchers at Fred Hutchinson Cancer Center made significant progress in immunotherapy for advanced Merkel cell carcinoma, with longer response times than standard chemotherapy. Precision prevention of colorectal cancer showed that preventing diseases may not be 'one size fits all', highlighting the need for tailored approaches. Addit...
Researchers discovered that prooxidants can repair a metabolic flaw in T cells that drive rheumatoid arthritis. Treating arthritic mice with ROS-inducing drugs restored the T cells' redox balance and reduced joint inflammation.
Researchers at Temple University Health System have successfully eliminated HIV-1 from the DNA of human T-cells using a specialized gene editing system. The technology not only removes the virus but also protects infected cells against reinfection, holding promise for an eventual cure for patients with HIV.
Researchers developed a differential immuno-capture technology that can detect sub-populations of white blood cells, including CD4+ T cells, for AIDS diagnosis. The microfluidic biosensor achieved over 90% correlation with flow cytometers in clinical trials.
Researchers developed a new technique called TraCeR that determines both the sequence of T-cell receptors in individual cells and each cell's gene expression profile. This allows for the study of how different populations of T cells respond to disease, enabling the exploration of immune responses in various conditions.
Researchers found that female mice with a mutated ITCH gene had reduced implantations and corpora lutea, as well as extended estrous cycles. The study suggests a potential role for ITCH in regulating reproductive function.
A particular enzyme called DLST in the TCA cycle supports the growth and survival of T-cell leukemia cells. Inhibiting this enzyme's activity can effectively kill these tumor cells.
Researchers at Fred Hutchinson Cancer Center have devised a new approach to engineer T cells with improved efficiency and tracking capabilities, potentially speeding up and improving T-cell therapy. The technology uses a small protein tag to purify and track the engineered T cells.
Researchers develop gene therapy using T cells to target cancer mutations, reducing side effects. The approach involves transferring tumor-specific T cell receptors into fresh T cells, enabling them to fight tumors.
Researchers have identified antigens that activate autoreactive T cells in autoimmune diabetes, a potential trigger for the disease. The discovery provides insight into how the immune system is tricked into destroying the body's own beta cells.
Researchers identified hybrid insulin peptides (HIPs) that trigger autoimmune response in T1D patients, prompting immune system to attack insulin-producing cells. These findings may help explain the mystery of why people with T1D are affected by incorrect insulin peptide bonding.
Researchers at UT Austin found that a type of cancer in children grows only when signaled by nearby noncancerous cells. This discovery contributes to the growing field of environmental research on cancer spread and holds promise for new, less toxic treatments.
Exercise scientists at BYU found that the immune system's T-cells infiltrate damaged muscle fibers, facilitating accelerated repair and reduced muscle soreness after repeated exercise bouts. This discovery challenges previous assumptions about inflammation and its role in exercise-induced muscle damage.
A new NIH-funded study suggests that changes in immune cell subtypes after oral immunotherapy for peanut allergy can help predict treatment success. The research, published in Proceedings of the National Academy of Sciences, found a novel T-cell population that likely would not mount an allergic response expanded with treatment.
A study found that taking high-dose vitamin D3 supplements can reduce the percentage of T cells related to MS activity, leading to a decrease in interleukin 17 levels. The results suggest that vitamin D may be an inexpensive, safe, and convenient treatment option for people with multiple sclerosis.
The La Jolla Institute will characterize immune responses to dengue virus and Mycobacterium tuberculosis with the HIPC grant. The research aims to identify effective gene signatures for vaccines against these diseases, which are major global health challenges.
Researchers at the University of Montreal Hospital Research Centre have developed a new injectable biogel that can deliver anti-cancer agents directly into cancerous tumours. The biogel is effective in killing cancer cells and has shown promising results in laboratory tests, including the destruction of melanoma and kidney cancer cells.
A University of Georgia researcher found that low levels of vitamin D can hinder the effectiveness of HIV treatment in adults. Participants with sufficient vitamin D levels recovered more of their immune function, on average 65 CD4+T cells more, compared to those with deficiency.
Scientists developed JEDI T-cells to visualize immune responses and model disease states, enabling targeted cell depletion and advancing immunotherapy in cancer care. This breakthrough has implications for autoimmune diseases and brain malignancies like glioblastoma.
Researchers created a new form of BanLec that fights AIDS, hepatitis C, and influenza viruses without causing inflammation. The engineered lectin molecule works by targeting the sugar code on virus surfaces and preventing them from entering cells.
Blood T cells are resistant to HIV's primary death pathway, but not lymphoid tissue T cells. The researchers suggest that studying lymphoid tissue T cells could lead to a better understanding of the virus and potentially new treatments.
Researchers have developed a molecular 'on switch' to control T cell actions in cancer therapy, allowing for sharper reduction of severe side effects. The innovation enables doctors to precisely manage immune responses using a controller drug that flips cells into an active status.
Investigators found that inhibiting TNFR2 can alleviate intestinal inflammation in mice, suggesting a new therapeutic approach for patients with IBD who do not respond to anti-TNF medications. This discovery could lead to new treatment options for the 65% of individuals with IBD who do not respond or become resistant to current therapies.
Researchers have identified the protein marker Bim as a potential predictor for patient response to PD-1 immunotherapy for melanoma. Patients with high levels of Bim and soluble PD-L1 are more likely to respond to treatment, suggesting that this biomarker may help clinicians predict which patients will benefit from PD-1 blockade.
A simple blood test can detect early markers of reinvigorated T cells and track immune responses in metastatic melanoma patients after initial treatment with pembrolizumab. The study found increased levels of proteins characteristic of reinvigoration in CD8+ T cells, suggesting a potential biomarker to predict patient response.
A new study reveals how immune cells, such as neutrophils and T cells, coordinate their efforts to fight infections. By understanding this teamwork, scientists hope to develop new ways to control and improve the body's response to illnesses like multiple sclerosis and lupus.
Researchers engineered CAR T cells to preferentially target cancer cells expressing high amounts of epithelial growth factor receptor (EGFR), while sparing normal cells. The modified cells were selectively activated only in response to cancer cells, demonstrating improved safety and efficacy in treating solid tumors.
Researchers developed a new system to fine-tune the affinity of CAR T cells, enabling them to selectively target cancer cells. The newly engineered cells showed more potent reactivity against tumor cells expressing high levels of specific proteins.
Researchers found that HIV's cell-to-cell transmission is the primary mechanism for massive CD4 T cell death, leading to the progression from HIV to AIDS. Disrupting this transmission effectively stopped cell death.
T cells' activation relies on a dynamic protein network at the cell surface, with proteins coming and going in rapid intervals. Understanding this process could help boost the immune response against diseases like cancer or infections.
Researchers have made significant progress in editing human T cells using CRISPR/Cas9, opening doors to potential therapies for autoimmune diseases, AIDS, and cancer. By disabling key proteins such as CXCR4 and PD-1, scientists hope to develop new treatments for various health problems.
A new T cell receptor therapy achieved a clinical response in 80% of multiple myeloma patients with advanced disease. The treatment, which targets cancer cells expressing NY-ESO-1, showed no cytokine release syndrome cases and impressive durable T cell persistence.
Researchers at Rockefeller University discovered that high affinity B cells divide faster during the antibody selection process, giving them an advantage. This discovery builds on earlier work and may have important implications for improving vaccines and understanding lymphomas.
Researchers found that subcutaneous administration of multispecific antibodies improves tumor treatment by better tolerability and undiminished effectiveness. The study suggests that this method could lead to broader availability of tumor treatment for patients, potentially eliminating hospitalization.
Professor Shashi Murthy is developing a novel microfluidic system to automate the process of creating dendritic cells, essential for effective vaccines. The new instrument aims to reduce the manual process from 16 steps to a fully-automated system, potentially cutting timeframes to six days.
Researchers have identified a new genetic immune disorder, DOCK2 deficiency, which causes debilitating infections and combined immunodeficiency in children. Early screening for the disease can prevent life-threatening infections, and understanding its role may inform the study of more common immune system disorders.
Researchers discovered that mutations in the AIRE gene can cause a milder form of Autoimmune polyendocrine syndrome type-1, affecting fewer organs and appearing later in life. This finding suggests that dominant AIRE-mutation autoimmune disease may be responsible for various autoimmune syndromes.
Scientists have identified a gene variant in wild chimpanzees that encodes an HIV-fighting protein, suggesting that hominids have been fighting off HIV-like viruses for at least five million years. The discovery could yield insights into biological and pharmaceutical applications to enhance HIV-infected people's survival.
Researchers have identified the Clec16a gene as a regulator of T cell education, which is central to the development of autoimmunity. The study shows that turning off the gene protects mice from developing diabetes, suggesting its role in preventing autoimmune diseases.
Researchers at the University of Chicago have identified a cell-intrinsic cancer-causing pathway that disrupts T cell infiltration in melanoma, enabling tumors to evade immune surveillance. Disrupting this signaling pathway could help restore T cell access and enhance the potential of immune-mediated cancer treatment.
Researchers from Penn Medicine and the Perelman School of Medicine will engineer T cells to be resistant to HIV-1 infection using a new gene therapy approach. The project aims to make more CD4 T cells resistant to the virus, re-invigorating the immune response.
A study led by St. Jude Children's Research Hospital scientists identified a protein called NLRP12 that helps regulate inflammation in T cells. The findings suggest how mutations in the Nlrp12 gene cause disease, paving the way for developing targeted therapies to ease symptoms of autoinflammatory diseases like multiple sclerosis and c...
Researchers successfully migrated immune cells to tumor sites in patients with mesothelin-expressing tumors. The treatment showed no major adverse events, suggesting patients tolerated it well, with T cells targeting and surviving at tumor sites for up to 28 days.
Erik Wambre, PhD, at Benaroya Research Institute will study T cells causing peanut allergy and analyze genes to neutralize these cells. The goal is to develop new approaches for diagnosis and treatment of food allergies.
Researchers have developed a multifaceted approach to identify drug combinations that reverse HIV-1 latency. Several 2-drug combinations were found to be able to reactivate HIV-1 without triggering an inflammatory response, and a model was created to correlate changes in viral RNA with virus secretion from T cells.
A new study reveals that mucosal-associated invariant T (MAIT) cells are dramatically reduced in individuals with type 2 diabetes and severe obesity, yet abundant in adipose tissue. MAIT cell abnormalities may contribute to obesity-associated metabolic alterations after weight loss restored circulating MAIT cells.
A preclinical study by the University of Pennsylvania School of Medicine found engineered T cells to be both safe and effective at controlling tumor growth in mice with glioblastoma. The CAR T cells target a mutation in the epidermal growth factor receptor protein called EGFRvIII, found on about 30% of glioblastoma patients' tumor cells.
Researchers have developed an alternative method to isolate CD4+ T cells, enabling HIV monitoring at a lower cost. The use of glass microbubbles, which are readily available and affordable, allows for the separation of target cells from unwanted cells.
Researchers found that γδ T cells contribute to systemic insulin resistance in obese mice by promoting low-grade inflammation in fat tissue. The study suggests that targeting γδ T cells may provide a new avenue for treating or preventing type 2 diabetes caused by obesity.
Byproducts from gum disease bacteria can reactivate dormant HIV in T-cells, leading to higher virus replication. This discovery highlights the significance of treating periodontal disease early for individuals with HIV infections.
Researchers have successfully treated patients with advanced CD19-positive hematologic malignancies using CAR T cells, achieving complete remission in some cases. The study used the Sleeping Beauty non-viral transduction system to modify T cells, demonstrating further promise in treating lymphoid malignancies.
In a groundbreaking clinical trial, nivolumab achieved complete or partial remission in 87% of patients with resistant Hodgkin lymphoma. The treatment targets the immune system, reactivating T cells to attack cancer cells.
New immunotherapy treatments aim to enable the body's natural defenses to recognize and destroy malignant cells. Studies present promising early data that encourage long-term outcomes among patients who have not responded to other therapies, including checkpoint inhibitors and drugs targeting the PD-1 pathway.
Scientists at VCU Massey Cancer Center use computer modeling to predict which patients are at greatest risk for developing GVHD after stem cell transplantation. The researchers found that minor histocompatibility antigens play a crucial role in shaping the development of T-cell clonal families.
Research shows that starting HIV therapy soon after infection significantly reduces the risk of developing AIDS and improves immune function, particularly when treatment is initiated within 12 months of seroconversion. A normal CD4+ T-cell count above 800 cells per cubic millimeter is crucial for reconstituting immune-fighting cells.
A new study suggests that starting HIV treatment within a year of seroconversion can improve immune health by increasing CD4+ T-cell count. Researchers found that an HIV-infected person's CD4+ T-cell count is more likely to return to normal if treatment starts within a year and at a CD4+ T-cell count of 500 or more.
A new study reveals that targeting specific immune cells in the gut can reduce the risk of HIV transmission by 2.7 times. The findings suggest that existing drugs for inflammatory bowel diseases could be effective in treating or preventing HIV infection.
A new study by University of California, San Francisco researchers has discovered a rare population of immune cells associated with less severe cancer outcomes in humans. These 'good' cells, known as antigen-presenting CD103+ dendritic cells, are found in most tumors and may hold therapeutic potential.